Fulcrum Therapeutics, Inc. (FULC)
Largest Insider Buys in Sector
FULC Stock Price History Chart
FULC Stock Performance
About Fulcrum Therapeutics, Inc.
Fulcrum Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing products for improving the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its product candidates are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy; and FTX-6058, an investigational oral fetal hemoglobin inducer for the treatment of sickle cell disease and other hemoglobinopathies, including beta-thalassemia. The company is also discovering drug targets for the treatments of rare neuromuscular, muscular, central nervous system, and hematologic disorders, as well as cardiomyopathies and pulmonary diseases. Fulcrum Therapeutics, Inc. has research and discovery collaboration agreement with Acceleron Pharma Inc. to identify biological targets to modulate specific pathways associated with a targeted indication within the pulmonary disease space; and has a strategic collaboration and license agreement with MyoKardia, Inc. to discover, develop, and commercialize novel targeted therapies for the treatment of genetic cardiomyopathies. Fulcrum Therapeutics, Inc. was Incorporated in 2015 and is headquartered in Cambridge, Massachusetts.
Insider Activity of Fulcrum Therapeutics, Inc.
Over the last 12 months, insiders at Fulcrum Therapeutics, Inc. have bought $492,028 and sold $59,050 worth of Fulcrum Therapeutics, Inc. stock.
On average, over the past 5 years, insiders at Fulcrum Therapeutics, Inc. have bought $14.91M and sold $1.5M worth of stock each year.
Highest buying activity among insiders over the last 12 months: Sapir Alex (See Remarks) — $492,028.
The last purchase of 43,360 shares for transaction amount of $492,028 was made by Sapir Alex (See Remarks) on 2024‑03‑04.
List of Insider Buy and Sell Transactions, Fulcrum Therapeutics, Inc.
| 2024-05-07 | Sale | Tourangeau Greg | Principal Accounting Officer | 236 0.0004% | $7.76 | $1,831 | +1.72% | |
| 2024-03-08 | Sale | Tourangeau Greg | Vice President, Finance | 4,884 0.0084% | $11.72 | $57,219 | -30.19% | |
| 2024-03-04 | Sapir Alex | See Remarks | 43,360 0.0707% | $11.35 | $492,028 | -31.57% | ||
| 2023-05-10 | Sale | Tourangeau Greg | Principal Accounting Officer | 210 0.0004% | $3.31 | $695 | +46.79% | |
| 2023-01-20 | RA CAPITAL MANAGEMENT, L.P. | director | 1.92M 3.8009% | $13.00 | $25M | -68.65% | ||
| 2023-01-13 | Sale | Gould Robert J | Interim President & CEO | 6,766 0.0142% | $15.00 | $101,490 | -71.09% | |
| 2023-01-04 | RA CAPITAL MANAGEMENT, L.P. | director | 180,703 0.3049% | $7.28 | $1.31M | -52.11% | ||
| 2022-12-27 | RA CAPITAL MANAGEMENT, L.P. | director | 4,089 0.009% | $5.99 | $24,510 | -34.35% | ||
| 2022-12-19 | RA CAPITAL MANAGEMENT, L.P. | director | 98,787 0.2145% | $5.90 | $582,814 | -34.35% | ||
| 2022-12-16 | RA CAPITAL MANAGEMENT, L.P. | director | 1.34M 3.0203% | $5.42 | $7.27M | -25.98% | ||
| 2022-12-15 | RA CAPITAL MANAGEMENT, L.P. | director | 237,029 0.5283% | $5.50 | $1.3M | -27.65% | ||
| 2022-12-14 | RA CAPITAL MANAGEMENT, L.P. | director | 824,600 1.8392% | $5.46 | $4.5M | -27.11% | ||
| 2022-06-07 | Sale | Gould Robert J | 71,435 0.1753% | $8.09 | $577,895 | -23.70% | ||
| 2022-06-02 | Sale | Gould Robert J | 16,689 0.043% | $7.92 | $132,162 | -16.89% | ||
| 2022-04-07 | Sale | Gould Robert J | 5,631 0.0145% | $24.02 | $135,228 | -68.29% | ||
| 2022-04-01 | Sale | Gould Robert J | 52,552 0.1313% | $24.26 | $1.27M | -69.08% | ||
| 2021-08-11 | Sale | Stuart Bryan | See Remarks | 28,000 0.0899% | $23.75 | $665,000 | -25.57% | |
| 2021-08-10 | Sale | Stuart Bryan | See Remarks | 32,000 0.0815% | $17.50 | $560,000 | -19.71% | |
| 2021-08-10 | Sale | Moxham Christopher | Chief Scientific Officer | 51,785 0.1326% | $17.60 | $911,416 | -19.71% | |
| 2021-06-28 | GERAGHTY JAMES A | director | 10,000 0.0312% | $9.16 | $91,600 | +68.04% |
Insider Historical Profitability
| Sapir Alex | See Remarks | 43360 0.07% | $6.17 | 1 | 0 | |
| Tourangeau Greg | Principal Accounting Officer | 11571 0.0259% | $6.17 | 0 | 3 | |
| RA CAPITAL MANAGEMENT, L.P. | director | 11609704 18.7791% | $6.17 | 7 | 0 | <0.0001% |
| LEVIN MARK J | 5962202 9.644% | $6.17 | 1 | 0 | +2.11% | |
| Third Rock Ventures III, L.P. | 10 percent owner | 5962202 9.644% | $6.17 | 1 | 0 | +2.11% |
| Third Rock Ventures IV, L.P. | 10 percent owner | 2343154 3.7901% | $6.17 | 1 | 0 | +2.11% |
| Casdin Capital, LLC | 10 percent owner | 604285 0.9774% | $6.17 | 1 | 0 | +2.11% |
| 6 Dimensions Capital, L.P. | 10 percent owner | 559821 0.9055% | $6.17 | 1 | 0 | +2.11% |
| Sanofi | 10 percent owner | 558035 0.9026% | $6.17 | 1 | 0 | +2.11% |
| Gould Robert J | Interim President & CEO | 499864 0.8085% | $6.17 | 0 | 21 | |
| Wallace Owen B. | Chief Scientific Officer | 127088 0.2056% | $6.17 | 0 | 6 | |
| GERAGHTY JAMES A | director | 90714 0.1467% | $6.17 | 1 | 0 | +68.04% |
| Cadavid Diego | SVP Clinical Development | 65714 0.1063% | $6.17 | 0 | 12 | |
| Thomson Peter G. | VP Finance & Accounting | 2300 0.0037% | $6.17 | 1 | 5 | +68.04% |
| Oltmans Curtis Gale | SVP, General Counsel | 1088 0.0018% | $6.17 | 1 | 0 | +68.04% |
| Morabito Christopher | Chief Medical Officer | 1100 0.0018% | $6.17 | 1 | 0 | +68.04% |
| Stuart Bryan | See Remarks | 0 0% | $6.17 | 0 | 2 | |
| Moxham Christopher | Chief Scientific Officer | 0 0% | $6.17 | 0 | 1 |
Institutional Investor Ownership
| RA Capital Management, L.P. | $109.6M | 18.68 | 11.61M | 0% | +$0 | 0.11 | |
| RTW Investments, LP | $55.19M | 9.41 | 5.85M | +6.87% | +$3.55M | 0.82 | |
| Fidelity Investments | $50.64M | 8.63 | 5.36M | -5.63% | -$3.02M | <0.01 | |
| Cowen Group | $35.06M | 5.98 | 3.71M | +6.91% | +$2.27M | 1.11 | |
| Suvretta Capital Management, LLC | $26.89M | 4.58 | 2.85M | -48.39% | -$25.21M | 1.14 | |
| The Vanguard Group | $23.96M | 4.08 | 2.54M | +0.74% | +$176,348.64 | <0.0001 | |
| Trv Gp Iv Llc | $22.12M | 3.77 | 2.34M | 0% | +$0 | 10.72 | |
| BlackRock | $14.55M | 2.48 | 1.54M | -1.32% | -$195,002.08 | <0.0001 | |
| Citadel Advisors LLC | $12.51M | 2.13 | 1.33M | -5.59% | -$740,983.37 | 0.01 | |
| Dimensional Fund Advisors | $12.32M | 2.1 | 1.3M | +33.79% | +$3.11M | <0.01 | |
| Morgan Stanley | $10.92M | 1.86 | 1.16M | -5.08% | -$584,543.67 | <0.01 | |
| Jefferies Financial Group | $10.87M | 1.85 | 1.15M | -19.65% | -$2.66M | 0.2 | |
| Bioimpact Capital Llc | $10.73M | 1.83 | 1.14M | New | +$10.73M | 1.74 | |
| Adage Capital Partners Gp L L C | $10.44M | 1.78 | 1.11M | -26.55% | -$3.78M | 0.02 | |
| Millennium Management LLC | $8.47M | 1.44 | 897,461 | +105.13% | +$4.34M | 0.01 | |
| Deutsche Bank | $7.77M | 1.32 | 823,098 | 0% | +$0 | <0.01 | |
| Goldman Sachs | $7.65M | 1.3 | 810,270 | -7.03% | -$578,039.54 | <0.01 | |
| ROCK SPRINGS CAPITAL MANAGEMENT, LP | $6.87M | 1.17 | 727,673 | 0% | +$0 | 0.18 | |
| Qube Research & Technologies | $6.83M | 1.16 | 723,163 | +197.71% | +$4.53M | 0.01 | |
| Simplify Asset Management Inc | $6.38M | 1.09 | 676,031 | +20.01% | +$1.06M | 0.61 | |
| D. E. Shaw & Co. | $5.9M | 1.01 | 625,176 | +25.62% | +$1.2M | 0.01 | |
| Geode Capital Management | $5.32M | 0.91 | 563,458 | +1.85% | +$96,578.79 | <0.0001 | |
| Susquehanna International Group | $5.3M | 0.9 | 560,992 | -15.84% | -$996,873.35 | 0.01 | |
| Affinity Asset Advisors | $5.2M | 0.89 | 550,339 | +340.27% | +$4.02M | 0.92 | |
| Jane Street Capital | $5.05M | 0.86 | 535,062 | +54.26% | +$1.78M | 0.01 | |
| Invesco | $4.69M | 0.8 | 496,679 | +4.3% | +$193,265.13 | <0.01 | |
| Two Sigma Advisers LP | $3.97M | 0.68 | 420,200 | -15.32% | -$717,440.00 | 0.01 | |
| Silverarc Capital Management Llc | $3.76M | 0.64 | 398,436 | New | +$3.76M | 1.11 | |
| Caption Management Llc | $2.98M | 0.51 | 315,460 | New | +$2.98M | 0.09 | |
| Bessemer Group Inc | $2.71M | 0.46 | 286,988 | 0% | +$0 | 0.01 | |
| State Street | $2.42M | 0.41 | 256,861 | +40.25% | +$695,860.21 | <0.0001 | |
| Standard Life | $2.43M | 0.41 | 256,888 | 0% | +$0 | 0.01 | |
| Marshall Wace | $2.13M | 0.36 | 225,573 | -55.34% | -$2.64M | <0.01 | |
| Point72 Asset Management | $2.11M | 0.36 | 223,400 | New | +$2.11M | <0.01 | |
| Mass General Brigham Inc | $1.94M | 0.33 | 205,356 | New | +$1.94M | 3.39 | |
| Alyeska Investment Group L P | $1.91M | 0.33 | 202,148 | 0% | +$0 | 0.01 | |
| AllianceBernstein | $1.76M | 0.3 | 186,965 | -21.92% | -$495,534.03 | <0.01 | |
| Citigroup | $1.69M | 0.29 | 178,564 | -37.41% | -$1.01M | <0.01 | |
| Two Sigma | $1.65M | 0.28 | 175,224 | -33.06% | -$816,824.54 | <0.01 | |
| Wellington Management Company | $1.63M | 0.28 | 172,660 | New | +$1.63M | <0.0001 | |
| Cubist Systematic Strategies | $1.62M | 0.28 | 171,507 | New | +$1.62M | 0.02 | |
| JPMorgan Chase | $1.5M | 0.26 | 158,935 | +1,289.29% | +$1.39M | <0.0001 | |
| HSBC | $1.41M | 0.24 | 149,627 | New | +$1.41M | <0.01 | |
| Cibc World Markets Corp | $1.42M | 0.24 | 150,000 | New | +$1.42M | 0.01 | |
| Laurion Capital Management LP | $1.37M | 0.23 | 144,721 | 0% | +$0 | 0.04 | |
| RBF Capital, LLC | $1.32M | 0.23 | 140,000 | 0% | +$0 | 0.08 | |
| Fiduciary Trust Co | $1.29M | 0.22 | 136,555 | 0% | +$0 | 0.02 | |
| Northern Trust | $1.29M | 0.22 | 136,433 | -5.89% | -$80,542.11 | <0.0001 | |
| Opaleye Management Inc | $1.23M | 0.21 | 130,000 | 0% | +$0 | 0.19 | |
| Hrt Financial Llc | $1.16M | 0.2 | 123,408 | New | +$1.16M | 0.01 |